<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38655026</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2732-494X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Antimicrobial stewardship &amp; healthcare epidemiology : ASHE</Title><ISOAbbreviation>Antimicrob Steward Healthc Epidemiol</ISOAbbreviation></Journal><ArticleTitle>The effectiveness of the COVID-19 vaccines in the prevention of post-COVID conditions in children and adolescents: a systematic literature review and meta-analysis.</ArticleTitle><Pagination><StartPage>e54</StartPage><MedlinePgn>e54</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e54</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/ash.2024.42</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">We performed a systematic literature review and meta-analysis on the effectiveness of coronavirus disease 2019 (COVID-19) vaccination against post-COVID conditions (long COVID) in the pediatric population.</AbstractText><AbstractText Label="DESIGN" NlmCategory="UNASSIGNED">Systematic literature review/meta-analysis.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched PubMed, Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from December 1, 2019, to August 14, 2023, for studies evaluating the COVID-19 vaccine effectiveness against post-COVID conditions among vaccinated individuals &lt; 21 years old who received at least 1 dose of COVID-19 vaccine. A post-COVID condition was defined as any symptom that was present 4 or more weeks after COVID-19 infection. We calculated the pooled diagnostic odds ratio (DOR) (95% CI) for post-COVID conditions between vaccinated and unvaccinated individuals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Eight studies with 23,995 individuals evaluated the effect of vaccination on post-COVID conditions, of which 5 observational studies were included in the meta-analysis. The prevalence of children who did not receive COVID-19 vaccines ranged from 65% to 97%. The pooled prevalence of post-COVID conditions was 21.3% among those unvaccinated and 20.3% among those vaccinated at least once. The pooled DOR for post-COVID conditions among individuals vaccinated with at least 1 dose and those vaccinated with 2 doses were 1.07 (95% CI, 0.77-1.49) and 0.82 (95% CI, 0.63-1.08), respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">A significant proportion of children and adolescents were unvaccinated, and the prevalence of post-COVID conditions was higher than reported in adults. While vaccination did not appear protective, conclusions were limited by the lack of randomized trials and selection bias inherent in observational studies.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gutfreund</LastName><ForeName>Maria Celidonio</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4751-6859</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Callado</LastName><ForeName>Gustavo Yano</ForeName><Initials>GY</Initials><Identifier Source="ORCID">0000-0001-6694-6569</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardo</LastName><ForeName>Isabele</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Mariana Kim</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perencevich</LastName><ForeName>Eli N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salinas</LastName><ForeName>Jorge L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases &amp; Geographic Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Edmond</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Department of Medicine, West Virginia University School of Medicine, Morgantown, WV, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendon&#xe7;a</LastName><ForeName>Eneida</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Luiz Vicente</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Alexandre R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-7577-7688</Identifier><AffiliationInfo><Affiliation>Faculdade Israelita de Ci&#xea;ncias da Sa&#xfa;de Albert Einstein, Hospital Israelita Albert Einstein, S&#xe3;o Paulo, SP, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Access &amp; Delivery Research &amp; Evaluation (CADRE), Iowa City Veterans Affairs Health Care System, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Antimicrob Steward Healthc Epidemiol</MedlineTA><NlmUniqueID>9918266096106676</NlmUniqueID><ISSNLinking>2732-494X</ISSNLinking></MedlineJournalInfo><CoiStatement>All authors report no conflict of interest relevant to this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>14</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>14</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>24</Day><Hour>3</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38655026</ArticleId><ArticleId IdType="pmc">PMC11036435</ArticleId><ArticleId IdType="doi">10.1017/ash.2024.42</ArticleId><ArticleId IdType="pii">S2732494X24000421</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol 2021;12:714170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8542872</ArticleId><ArticleId IdType="pubmed">34707602</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. Int J Infect Dis: IJID: Offic Publ Int Soc Infect Dis 2022;114:252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8595975</ArticleId><ArticleId IdType="pubmed">34800687</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. Long COVID or Post-COVID Conditions. https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. Published 2022. Accessed May 20, 2022</Citation></Reference><Reference><Citation>Pellegrino R, Chiappini E, Licari A, Galli L, Marseglia GL. Prevalence and clinical presentation of long COVID in children: a systematic review. Eur J Pediatr 2022;181:3995&#x2013;4009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9476461</ArticleId><ArticleId IdType="pubmed">36107254</ArticleId></ArticleIdList></Reference><Reference><Citation>Principi N, Esposito S. Reasons in favour of universal vaccination campaign against COVID-19 in the pediatric population. Ital J Pediatr 2022;48:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743738</ArticleId><ArticleId IdType="pubmed">35012590</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliver SE, Wallace M, Link-Gelles R. COVID-19 vaccines: safe and effective in children aged 5 to 11 years. Pediatrics 2022;150:e2022057314.</Citation><ArticleIdList><ArticleId IdType="pubmed">35581697</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiri T, Evans M, Talarico CA, et al. Vaccinating adolescents and children significantly reduces COVID-19 morbidity and mortality across all ages: a population-based modeling study using the UK as an example. Vaccines 2021;9:1180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8537561</ArticleId><ArticleId IdType="pubmed">34696288</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Kobayashi T, Callado GY, et al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research. Antimicrob Steward Healthc Epidemiol 2023;3:e168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10644173</ArticleId><ArticleId IdType="pubmed">38028898</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">10789670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto Pereira SM, Nugawela MD, Rojas NK, et al. Post-COVID-19 condition at 6 months and COVID-19 vaccination in non-hospitalised children and young people. Arch Dis Child 2023;108:289&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10086284</ArticleId><ArticleId IdType="pubmed">36599625</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokanuwatsatien T, Satdhabudha A, Tangsathapornpong A, et al. Prevalence and associating factors of long COVID in pediatric patients during the Delta and the Omicron variants. Front Pediatr 2023;11:1127582.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10244785</ArticleId><ArticleId IdType="pubmed">37292374</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998;52:377&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1756728</ArticleId><ArticleId IdType="pubmed">9764259</ArticleId></ArticleIdList></Reference><Reference><Citation>Alderson P, Green S, Higgins JP, editors. Assessment of Study Quality. Cochrane Reviewer&#x2019;s Handbook 4.2.3 [Updated November 2004]. Chichester, UK: John Wiley &amp; Sons, Ltd; 2004.</Citation></Reference><Reference><Citation>Doebler P, Holling H., Sousa-Pinto B. Meta-analysis of diagnostic accuracy with mada. R. package version 0.5.8. URL: Meta-Analysis of Diagnostic Accuracy with mada (r-project.org). Published 2017. Accessed February 28, 2024.</Citation></Reference><Reference><Citation>Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982&#x2013;990.</Citation><ArticleIdList><ArticleId IdType="pubmed">16168343</ArticleId></ArticleIdList></Reference><Reference><Citation>Goto M, Ohl ME, Schweizer ML, Perencevich EN. Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. Clin Infect Dis: Offic Publ Infect Dis Soc Am 2014;58:688&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pubmed">24218103</ArticleId></ArticleIdList></Reference><Reference><Citation>Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software 2010;36:1&#x2013;48.</Citation></Reference><Reference><Citation>Adler L, Israel M, Yehoshua I, et al. Long COVID symptoms in Israeli children with and without a history of SARS-CoV-2 infection: a cross-sectional study. BMJ Open 2023;13:e064155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9944622</ArticleId><ArticleId IdType="pubmed">36810170</ArticleId></ArticleIdList></Reference><Reference><Citation>Atchison CJ, Whitaker M, Donnelly CA, et al. Characteristics and predictors of persistent symptoms post-COVID-19 in children and young people: a large community cross-sectional study in England. Arch Dis Child 2023;108:e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313975</ArticleId><ArticleId IdType="pubmed">36863848</ArticleId></ArticleIdList></Reference><Reference><Citation>Ertesv&#xe5;g NU, Iversen A, Blomberg B, et al. Post COVID-19 condition after delta infection and omicron reinfection in children and adolescents. EBioMedicine 2023;92:104599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10166589</ArticleId><ArticleId IdType="pubmed">37149931</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarupan M, Jantarabenjakul W, Jaruampornpan P, et al. Long COVID and hybrid immunity among children and adolescents post-delta variant infection in Thailand. Vaccines 2023;11:884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10223729</ArticleId><ArticleId IdType="pubmed">37242988</ArticleId></ArticleIdList></Reference><Reference><Citation>Messiah SE, Hao T, DeSantis SM, et al. Comparison of persistent symptoms following SARS-CoV-2 infection by antibody status in nonhospitalized children and adolescents. Pediatr Infect Dis J 2022;41:e409&#x2013;e417.</Citation><ArticleIdList><ArticleId IdType="pubmed">35939608</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R, Mariani F, Mastrantoni L, et al. Risk factors for post-COVID-19 condition (long COVID) in children: a prospective cohort study. EClinicalMedicine 2023;59:101961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberg A, Sawhney M, Bernstein HH, Romero JR. COVID-19 vaccines for children: an update. Pediatr Ann 2023;52:e83&#x2013;e88.</Citation><ArticleIdList><ArticleId IdType="pubmed">36881800</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne A, Thompson LA, Filipp SL, Ryan K. COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout. Vaccine 2022;40:6680&#x2013;6687.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9533673</ArticleId><ArticleId IdType="pubmed">36220714</ArticleId></ArticleIdList></Reference><Reference><Citation>Khemiri H, Ayouni K, Triki H, Haddad-Boubaker S. SARS-CoV-2 infection in pediatric population before and during the Delta (B.1.617.2) and Omicron (B.1.1.529) variants era. Virol J 2022;19:144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452867</ArticleId><ArticleId IdType="pubmed">36076271</ArticleId></ArticleIdList></Reference><Reference><Citation>Trapani G, Verlato G, Bertino E, et al. Long COVID-19 in children: an Italian cohort study. Ital J Pediatr 2022;48:83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9163526</ArticleId><ArticleId IdType="pubmed">35659358</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Anderson E, Berthaud V, et al. Evaluation of mRNA-1273 COVID-19 vaccine in children 6 to 11 years of age. N Engl J Med 2022;386:2011&#x2013;2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127699</ArticleId><ArticleId IdType="pubmed">35544369</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 2021;4:e2128568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Bygdell M, Kindblom JM, Martikainen J, Li H, Nyberg F. Incidence and characteristics in children with post-COVID-19 condition in Sweden. JAMA Netw Open 2023;6:e2324246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10357335</ArticleId><ArticleId IdType="pubmed">37466944</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Sampaio VS, Ozahata MC, et al. Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020&#x2013;2022. Infect Contr Hosp Epidemiol 2023;44:1972&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755155</ArticleId><ArticleId IdType="pubmed">37272468</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Cancela-Cilleruelo I, Rodr&#xed;guez-Jim&#xe9;nez J, et al. Associated-onset symptoms and post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, Alpha or Delta SARS-CoV-2 variant. Pathog 2022;11:725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta vs omicron variants of SARS-CoV-2. Lancet (London, England) 2022;399:2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-las-Pe&#xf1;as C, Rodr&#xed;guez-Jim&#xe9;nez J, Cancela-Cilleruelo I, et al. Post&#x2013;COVID-19 symptoms 2 years after SARS-CoV-2 Infection among hospitalized vs nonhospitalized patients. JAMA Netw Open 2022;5:e2242106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667330</ArticleId><ArticleId IdType="pubmed">36378309</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra AR, Kobayashi T, Suzuki H, et al. The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: a systematic literature review and meta-analysis. Antimicrob Steward Healthc Epidemiol: ASHE 2022;2:e192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9726631</ArticleId><ArticleId IdType="pubmed">36505947</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>